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ABSTRACT
Introduction: Breast cancer in young women
(\50 years) has been associated with an
increased risk of recurrence and decreased
survival compared with patients older than 50.
The objective of this analysis was to determine,
from a large database of patients with
early-stage breast cancer, if the Recurrence
Score result (Oncotype DX, Genomic Health,
Inc, Redwood City, CA, USA) provided clinically
meaningful differences in predicted risk of
recurrence in younger—compared with older—
patients.
Methods: Tumor samples from patients with
estrogen receptor (ER)-positive breast cancers
that were successfully processed in the Genomic
Health central lab between June 2004 and
December 2013 for Recurrence Score and
quantitative gene expression of ER,
progesterone receptor (PR), and Her/2neu,
were included. Descriptive statistics were used
to describe the distribution of scores by age
group: \40, 40–49, 50–59, 60–69, and
C70 years, nodal status, and histologic subtype.
Results: Specimens from 394,031 patients
[3.3% (n = 13,029) aged \40 years; 15.6%
(n = 61,643) aged C70 years] were included;
81.6% of patients had invasive ductal
carcinoma. Nodal status was specified for
362,001 patients (87.0% negative). Median
Recurrence Score results were similar across
risk groups. Low (\18)- and high (C31)- risk
Recurrence Score results were seen in 58.5% and
8.5% of patients, respectively. A greater
proportion of patients aged \40 (14.1%) than
C70 (8.8%) years had a high-risk score. ER
expression increased as a function of age and
PR single-gene and invasion gene group
expression were similar across age groups.
Conclusion: These data indicate that in
patients with ER-positive breast cancer, age
alone does not reflect the underlying
individual tumor biology, suggesting that the
Recurrence Score result may add potentially
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INTRODUCTION
Approximately, 5% of invasive breast cancers
occur in women under the age of 40 years [1]
and breast cancer is the leading cause of
cancer-related deaths in women between the
ages of 20–39 years [2]. Overall survival (OS)
rates are lower compared with those of older
women [3–5].
Young age is often delineated as
premenopausal (approximately\50 years) [6],
but much of the literature defines young age as
\35 or \40 years. Reports have attributed
worsening prognosis of young women to
biological factors, including lower estrogen
receptor/progesterone receptor (ER/PR)
expression [7, 8] or overexpression of human
epidermal growth factor receptor 2 (HER2) [9];
higher incidence of triple-negative disease
(TNBC; absence of PR, ER, and HER2) [10];
vascular invasion [7]; nodal status [8]; and
higher grade [5, 7]. Other reports found that
age conferred a worse prognosis, irrespective of
pathologic features [7], delay in diagnosis [11],
or higher treatment intensity, particularly in
women aged \35 years [12]. Therefore, young
age is frequently used as an indication for
recommendation of adjuvant chemotherapy.
The 21-gene assay Recurrence Score result
(Oncotype DX, Genomic Health, Inc, Redwood
City, CA, USA) provides the 10-year risk of
distant recurrence and predicts the likely
benefit of adding chemotherapy to endocrine
therapy in women with ER-positive (ER?) early
breast cancer. The Recurrence Score result has
now been incorporated into major clinical
guidelines for treatment decisions [13–17],
based on both the prognostic and predictive
information the score provides. Decisions
guided by the Recurrence Score result can
spare women the toxic effects of
chemotherapy, such as cardiotoxicity,
secondary cancers, and neurotoxicity [18–27],
based on the prediction of little to no benefit in
patients with a low score, as well as identifying
women with high risk of recurrence who are
likely to benefit meaningfully from
chemotherapy.
Overall, there are limited data regarding
age-specific biological differences and response
to therapy in young women with ER? disease.
The objective of the analyses in this paper was
to determine if the Recurrence Score result
provided clinically meaningful differences in
predicted risk of recurrence in younger
compared with older patients.
METHODS
All ER? [ER by reverse transcriptase-polymerase
chain reaction (RT-PCR) C6.5 threshold cycle]
tumor specimens that were successfully
examined in the Genomic Health (GHI)
central reference laboratory (as per methods
previously described) [28] from June 1, 2004
through December 31, 2013 were included in
these analyses. The 21-gene assay was
performed according to methods previously
described [29].
Statistical Analysis
Clinical data routinely submitted to GHI on the
requisition includes age, nodal status [indicated
as node-negative, node-positive (N?; 1–3
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positive nodes), or micrometastases], and tumor
grade (as determined by local laboratories). All
specimens were reviewed by GHI pathologists
for determination of histologic subtype.
Descriptive statistics were calculated for the
Recurrence Score result, single genes (ER, PR,
HER2), and gene groups (invasion index and
proliferation index). The distribution of
Recurrence Score results was analyzed
according to age, histology, and nodal status.
Age groups were delineated as \40, 40–49,
50–59, 60–69, and C70 years.
Data for categorical variables are reported as
the number of percent of observations.
Continuous variables are reported as the
median, mean, total range, and first and third
quartiles. Both categorical and continuous
variables are described within each age and
Recurrence Score risk group. Because of the
large size of the database, even small differences
across age groups were expected to lead to
statistically significant but not clinically
meaningful results. Therefore, all analyses were
descriptive. Analyses were performed on
de-identified data.
This article does not contain any new studies
with human or animal subjects performed by




The analysis included samples with successful
Recurrence Score results from 394,031 patients
in the GHI database (Table 1). More than 99% of
patients were aged 25–90 years. The majority
(81%) were aged 40–69 years; 3.3% (n = 13,029)
were \40 years, and 15.6% (n = 61,643) were
C70 years (Fig. 1). The most common histology
was invasive ductal [not otherwise specified
(NOS)] in 81.6% of patients. Nodal status was
specified for 362,001 patients, and 87.0%
(n = 314,875) were node-negative (Fig. 2).
The age spread among the patients in the
GHI database (N = 394,031) was also compared
to the age spread among patients with newly
diagnosed breast cancer in the American Cancer
Society (ACS) database (N = 232,340) [1].
Within the GHI and ACS databases, there were
a similar proportion of patients aged\40 (3.3%
and 4.7%), \50 (23.0% and 21.1%), and C50
(77.0% and 78.9%) years, respectively.
Distribution of Recurrence Score Risk
Groups
A wide range of Recurrence Score results and
risk stratification was observed within all age
groups (Figs. 3, 4). Overall, 58.5% (n = 230,529),
33.0% (n = 130,082), and 8.5% (n = 33,420) of
patients had a low (\18), intermediate (18–30),
or high (C31) Recurrence Score result,
respectively. The proportion of low- and
high-risk scores was comparable across the age
groups. Notably, a greater proportion of
patients aged \40 years appear to have high
Recurrence Score results compared with
patients aged C70 years (14.1% vs. 8.8%), and
the median score was slightly higher in patients
\40 years (18) and slightly lower in all other age
groups (medians for 40–49, 50–59, 60–69, and
C70-year groups were: 16, 17, 16, and 16,
respectively).
Histologic Subtypes and Distribution
of Recurrence Score Risk Groups by Age
Ductal carcinoma NOS accounted for 81.6% of
the histologic type overall and 78–85% across
the age groups with the highest proportion in
the \40-year group (84.7%) and the lowest
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proportion in theC70-year group (78.1%; Fig. 1).
Lobular-classical/solid/alveolar accounted for
8.0% overall and 3.7% in the \40-year group
with increasing proportion over the age groups
to 10.2% in the C70-year group.
Lobular-pleomorphic and medullary/
medullary-like accounted for 0.6% and 0.3%
overall, respectively. The distribution of
Recurrence Score results within histologic
subtypes was similar when further stratified by
age (Fig. 5). In patients with ductal carcinoma, a
lower proportion of patients aged \40 years
(46.9%) had low Recurrence Score results
compared with patients C70 years (58.2%).
Patients with medullary/medullary-like
histology had a greater proportion with high
(approximately 43%) scores and lower
proportion of low scores, and this pattern was
consistent across the age groups.
Distribution of Recurrence Score Results
by Age and Nodal Status
The distribution of Recurrence Score results by
nodal status (N = 362,001: node-negative,
n = 314,875; N?, n = 32,289; and
micrometastases [pNmi], n = 14,837) was
similar when stratified by age (Fig. 2). Within
each nodal group, proportionally fewer patients
\40 years had low-risk scores compared with
Table 1 Patient characteristics
Characteristic, n (%) Age group, years All patients
<40 40–49 50–59 60–69 ‡70





11,983 (3.3) 72,265 (20.0) 109,202 (30.2) 113,593 (31.4) 54,958 (15.2) 362,001 (100)
Negative 10,717 (3.0) 64,489 (17.8) 96,158 (26.6) 98,345 (27.2) 45,166 (12.5) 314,875 (87.0)
Positive (1–3
positive nodesa)
823 (0.2) 4938 (1.4) 8562 (2.4) 10,561 (2.9) 7405 (2.0) 32,289 (8.9)




11,041 (2.8) 64,843 (16.5) 96,668 (24.5) 100,874 (25.6) 48,114 (12.2) 321,540 (81.6)
Lobular-classical,
solid alveolar
476 (0.1) 4884 (1.2) 9032 (2.3) 10,972 (2.8) 6254 (1.6) 31,618 (8.0)
Lobular-pleomorphic 30 (\0.1) 358 (0.1) 630 (0.2) 892 (0.2) 503 (0.1) 2413 (0.6)
Medulary/
medullary-like
59 (\0.1) 207 (0.1) 377 (0.1) 328 (0.1) 130 (\0.1) 1101 (0.3)
Other/unknown 1423 (0.4) 7298 (1.9) 10,464 (2.7) 11,532 (2.9) 6642 (1.7) 37,359 (9.5)
NOS Not otherwise speciﬁed
a Less than 1% of patients have 4 positive nodes
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patients C70 years (node-negative: 48.3% vs.
59.7%; N?: 47.4% vs. 61.7%; pNmi: 51.5% vs.
63.7%). Accordingly, in patients with
micrometastases, a slightly higher proportion
of patients \40 years were classified as
intermediate or high risk, compared with
patients C70 years.
Comparison of Quantitative Gene
Expression by Age and Recurrence Score
Result
A wide range of quantitative ER and PR gene
expression, as well as the proliferation index
and invasion index, was observed within all age
groups. ER expression increased with increasing
age with a median of 9.3 in the\40-year group
and 10.6 in the C70-year group. There was a
slight decrease in PR expression across age
categories with medians of 7.8 and 7.5,
respectively. The maximum observed ER
values represented more than a 100-fold
greater RNA expression than the cutpoint for
positivity of 6.5 in all age groups. Expression of
the proliferation index and invasion index was
also similar across all age groups (Fig. 6).
An analysis of the ER and PR co-expression
by age group and Recurrence Score risk group is
shown in Fig. 7. Across all risk groups there was
a consistent pattern of increasing median ER
and decreasing median PR with increasing age.
Increases in median ER were most pronounced
in low-risk patients (9.5 in patients aged \40
years to 11.0 in patients aged C70 years),
although all median ER values were
substantially above the threshold for positivity
(6.5). Decreasing median PR expression as a
function of age was most pronounced in the
high-risk group (6.0 in patients aged\40 years
to 4.5 in patients aged C70 years).
Medullary/medullary-like (n = 1101)
Ductal carcinoma, NOS (n = 321,540)
Histologic subtype
Other/unknown (n = 37,359)
Lobular-classical, solid, alveolar (n = 31,618)
Lobular-pleomorphic (n = 2413)
Age <40 years Age 40–49 years Age 50–59 years





n = 13,029 (3.3%) n = 77,590 (19.7%) n = 117,171 (29.7%)
All patients























Fig. 1 Distribution of patients by age group and histologic
subtype (N = 394,031). Histologic types captured include:
Ductal (NOS); medullary/medullary-like; lobular-classical,
solid, alveolar; lobular-pleomorphic; other/unknown. Each
pie chart shows the proportion of histologic subtype within
each age group by decade starting with \40 years up to
C70 years. NOS not otherwise speciﬁed
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DISCUSSION
The 21-gene Recurrence Score result is widely
used in the United States to guide the addition
of adjuvant chemotherapy to endocrine therapy
[30–32]. While the overall treatment paradigm
has shifted substantially as a result, there
continues to be a more conservative approach
for treatment recommendations in younger
women. As age has been traditionally
associated with a poorer prognosis, young
women are more often offered chemotherapy,
irrespective of their Recurrence Score result.
Two of the studies validating the Recurrence
Score result included a lower proportion
(8.8–9.7%) of younger women [26, 33].
However, these studies and others have
consistently shown that the Recurrence Score
result provides prognostic and predictive
information independent of age and that there
is a broad range of scores across age categories
[34–37].
The GHI clinical laboratory has now
processed more than 394,000 samples over a
decade that includes 90,619 patients\50 years
and 13,029 \40 years. This has enabled us to
examine the distribution of the Recurrence
Score results across different age categories,
each of them including a large number of
patients. The age range in the GHI database
(N = 394,031) is comparable to Surveillance,
Epidemiology, and End Results (SEER) with a
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Fig. 2 Distribution of Recurrence Score risk group by age
group and nodal status (N = 362,001). a Distribution
across age groups in entire cohort (n = 394,031);
b node-negative patients (n = 314,875); c node-positive
patients (n = 32,289); d nodes with micrometastases
patients (n = 14,837). For b, c, and d, only patients with
speciﬁed nodal status were included. If ﬁeld was left
unmarked or if unknown, the patient was not included
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wide age distribution, ranging from 20 to
[85 years [38]. Within both datasets, fewer
patients were aged \35 or C85 years. In the
GHI dataset, we found that for all age
categories, there was a range of Recurrence
Score results irrespective of the histology or
nodal status and that the proportion of patients
in low-, intermediate-, and high-risk groups was
consistent with the overall dataset. The overall
distribution of Recurrence Score results in the
entire GHI dataset categorized 58.5% as low risk
and 8.5% as high risk. The distribution of
Recurrence Score results across the age
categories was consistent with the overall
cohort except for the \40-year group which
had a lower proportion of patients with low-risk
scores (48.2%) and a greater proportion of
high-risk scores (14.1%). Of note, the 40- to
49-year group had the highest proportion of
low-risk scores (60.1%) and the smallest
proportion of high-risk scores (7.4%). In
addition, there were small differences in the
median Recurrence Score results between
women aged \40 years and those aged C70
years (the higher median score of 18 was in
patients aged \40 years), and the Recurrence
Score result tended to decrease with advancing
age. Similar observations were made when
examining PR, proliferation index, and
invasion index, with small absolute differences
when data were stratified by age. ER values
showed a larger increase as a function of age.
Other prognostic factors in addition to
young age are also often used to determine
course of treatment. These include histology,
nodal status and older age (C70 years).
Numerous studies have shown that young age
at diagnosis is associated with poor outcome.
Although tumors diagnosed in younger women
often have more aggressive pathologic features,
the association with poor prognosis seems to be
present despite clinicopathologic factors, access
to health care, and type of treatment,
suggesting that breast cancer in young women
may have a unique tumor biology driving their
prognosis. The data regarding gene expression
patterns in young women are relatively limited.
A study looking at gene expression profiling in
3522 patients according to age (451 of patients
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Fig. 3 Distribution of Recurrence Score risk groups by age group (N = 394,031). The Recurrence Score risk groups and
proportion of patients within each risk and age group by decade starting with\40 years up to C70 years
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Fig. 4 Distribution of Recurrence Score results by age
group (N = 394,031), normalized by proportion of patients
in each age group (continuous Recurrence Score). a Patients
aged\40 years (n = 13,029); b patients aged 40–49 years
(n = 77,590); c patients aged 50–59 years (n = 117,171);
d patients aged 60–69 years (n = 124,598); e patients aged
C70 years (n = 61,643); f all patients (N = 394,031). The
dashed vertical line represented the median
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proportion of basal-like and HER2 enriched
breast cancer [39]. Among young women with
ER/PR? breast cancer, there was a lower
frequency of luminal A tumors. This study also
showed differential expression according to age
of several of the 50 genes included in the panel,
regardless of tumor subtype, grade, and stage.
When they looked at different prognostic gene
signatures, including three proliferation-related
signatures, they found that all proliferation
gene signatures added significant prognostic
information to Adjuvant Online, irrespective
of age. Other reports did not find their gene
panel differentially expressed according to age
when correcting for intrinsic subtype and other
clinicopathologic features (as grade, ER status,
and nodal status), leading to the conclusion
that treatment should be driven by subtype
biology and less influenced by age [40]. Our
large series shows that the Recurrence Score
result and the expression of invasion and
proliferation genes have a similar distribution
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Fig. 5 Distribution of Recurrence Score risk groups by age
group and by histologic subtype (N = 394,031). a Ductal
carcinoma (82%); b lobular-classical/solid/alveolar (8%);
c lobular-pleomorphic (0.6%); d medullary/medullary-like
(0.3%); e other/unknown (9%). NOS not otherwise
speciﬁed
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in all age groups, again suggesting that age on
its own is not necessarily a determinant of more
aggressive biologic behavior.
Among the 32,289 N? patients in our study,
there was a wide range of Recurrence Score
results (i.e., risk groups) observed in all age
groups. This suggests that the patients with N?
disease, across all ages, have tumors with
heterogeneous biologic characteristics and
prognosis. Our observations of decreasing
Recurrence Score values with increasing age
are consistent with prior reports in N? patients.
The prognostic impact of the Recurrence Score
result in pre- and post-menopausal N? women
was evaluated in a cohort of the NSABP B28
study, including 1065 patients with positive
nodes treated with adjuvant
doxorubicin/cyclophosphamide and tamoxifen
with or without paclitaxel [41]. In this study,
older patients and patients with small tumors
were more likely to have a low Recurrence Score


























































































































































































































13,029n = 77,590 117,171 124,598 61,643 394,031
9.3Median = 9.3 10.0 10.5 10.6 10.1
13,029n = 77,590 117,171 124,598 61,643 394,031
7.8Median = 8.1 7.5 7.5 7.5 7.6
13,029n = 77,590 117,171 124,598 61,643 394,031
5.7Median = 5.4 5.3 5.4 5.4 5.4
13,029n = 77,590 117,171 124,598 61,643 394,031
7.1Median = 6.9 7.0 7.0 7.0 7.0
Fig. 6 Comparison of quantitative gene expression scores
across age groupsa. A wide range of gene expression values
were observed within each age group for all gene expression
scores. Median ER levels increased with increasing age while
median PR levels decreased. Invasion gene group scores and
proliferation gene group scores appear similar across the age
groups. a ER by RT-PCR (?ER C 6.5); b PR by RT-PCR
(?PR C 5.5); c proliferation index; d invasion index.
aExcludes patients with ER-negative tumors (ER\6.5, by
RT-PCR). ER estrogen receptor, PR progesterone receptor,
RT-PCR reverse transcriptase-polymerase chain reaction
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different according to the number of positive
nodes. The Recurrence Score result was an
independent predictor of distant recurrence
beyond age (\50 and C50 years), both in
women with one to three nodes and in
women with four or more nodes involved.
Patients with four or more nodes involved
with a low score had a better outcome than
patients with lower nodal burden but a high
score. In addition to its prognostic information,
the Recurrence Score result has also been shown
to predict the benefit of adding adjuvant
chemotherapy to endocrine therapy in a
post-menopausal N? population. In the
SWOG S8814 trial, which looked at the
addition of chemotherapy to tamoxifen in
post-menopausal, N? patients, the Recurrence
Score result was a strong predictive factor of
benefit from chemotherapy for disease-free
survival [42].
Fig. 7 Quantitative ER and PR expression within age and
Recurrence Score risk groups. Joint analysis of ER and PR
expression within age and Recurrence Score risk groups
shows that a wide and overlapping range of ER and PR
expression is observed within age and risk groups. As with
the population as a whole, there is generally an increase in
median ER and a decrease in median PR with increasing
age. The decrease in PR is most pronounced in high-risk
patients. ER estrogen receptor, PR progesterone receptor,
RT-PCR reverse transcriptase-polymerase chain reaction
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Limitations of our analysis include the
absence of treatment information, other
clinicopathologic characteristics (e.g., size and
grade) and importantly, clinical outcomes.
However, the consistency in the proportion of
patients within each Recurrence Score risk
group across the age groups as well as within
nodal status and histologic subtypes is
consistent with the results from the validation
subgroup analysis of NSABP B-14, in which the
Recurrence Score result was shown to be
prognostic over all age groups [29]. Since we
did see a slightly greater proportion of high
scores in the younger age group, there is a
possibility that breast cancer in young women is
enriched with more aggressive subtypes.
However, within each age group, breast cancer
is heterogeneous and treatment decisions
should not be driven by age alone, especially if
the biology is favorable.
An additional limitation is a potential for
selection bias in that younger women with
higher grade tumors or other poor prognostic
clinical features would not get tested and
therefore be underrepresented. This could
impact the overall distribution of scores within
the age categories, but should not impact the
risk estimates associated with the individual
score result, which are derived from controlled
studies.
There are currently ongoing trials
prospectively evaluating the Recurrence Score
result and chemotherapy benefit prediction.
Two of the studies, the TAILORx
(ClincialTrials.gov identifier, NCT00310180;
N = 10,253) and RxPONDER (ClincialTrials.gov
identifier, NCT01272037; planned N = 4000)
trials in women with ER? and node-negative
or N? or early breast cancer, respectively, will
determine whether the addition of
chemotherapy to endocrine therapy is
beneficial to patients with a mid-range
Recurrence Score results (11–25 for
node-negative and B25 for N?). Although
specific analyses based on age are not planned
for the TAILORx and RxPONDER studies, all
ages between 18 and 75 years are eligible and
given the large sample size of the studies, it can
be expected that at least 20% will be\50 years
and approximately 10% \40 years based on
current demographics, which will allow
further opportunities to evaluate the effect of
age as a determinant of prognosis within the
different Recurrence Score groups.
Recently, the 5-year outcomes of the Study
Arm A of TAILORx (Recurrence Score
results\11) treated with hormone therapy
alone were reported [43]. Of the 10,253
patients enrolled, 1626 had Recurrence Score
results of\11; 430 (27%) were B50 years and 58
(4%) were B40 years and were similar in
proportion to the Study Arms B/C, which were
the randomized arms with scores of 11–25. The
5-year freedom from distant recurrence estimate
was 99.3% [95% confidence interval (CI):
98.7–99.6], the 5-year freedom from any
recurrence estimate was 98.7% (95% CI:
97.9–99.2), the disease-free survival was 93.8%
(95% CI: 92.4–94.9), and OS at 5 years was 98%
(95% CI: 97.1–98.6). In the multivariate
analysis, there was no significant difference in
recurrence risk by age (B50 vs. 51–60 vs.
61–75 years). The clinical significance of the
TAILORx Arm A results, as it pertains to this
analysis of close to 400,000 patients, is a
demonstration that patients with a low
Recurrence Score result (\11) treated with
appropriate hormone therapy have an
excellent outcome, will have little chance of
benefitting from addition of chemotherapy,
and that age, as a single factor, does not have
an impact.
The Recurrence Score result has significantly
affected the treatment paradigm for ER?
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early-stage breast cancer with a shift away from
chemotherapy for women with low scores.
However, the shift has not been as great in
younger women (\40 years). Strengths of this
analysis are the size of the dataset with over
390,000 patients, demonstrating consistency of
the distribution of Recurrence Score values
across age categories, as well as histologic
subtype, nodal status, ER/PR expression and
the proliferation and invasion index.
CONCLUSIONS
These results show that the Recurrence Score
result reflects tumor biology beyond age alone
and has clinical implications for both younger
and older patients with respect to optimizing
treatment decisions.
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